Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| 60 Degrees Pharmaceuticals Inc. | SJ733 with tafenoquine | P. uncomplicated P. vivax malaria | Phase 2b | Ongoing | oral | Antimalarial |
| 60 Degrees Pharmaceuticals Inc. | Tafenoquine Oral Tablet - (ACLR8-LR) | COVID-19 patients with mild-moderate symptoms and low risk of disease progression | Phase 2b | Withdrawn | Oral | COVID-19 |
| 60 Degrees Pharmaceuticals Inc. | ARAKODA (tafenoquine) | Babesiosis | Phase 2 | Ongoing | oral | Antibiotic |
| 60 Degrees Pharmaceuticals Inc. | ARAKODA regimen (tafenoquine) - (open label) - (B-FREE) | Chronic babesiosis in outpatient settings | Phase 2 | Trial Planned | oral | Antimalarial |
| Aardvark Therapeutics Inc. | ARD-101 - (HERO) | Prader-Willi Syndrome | Phase 3 | Enrollment Initiation | Oral | Genetic Disorder |
| Aardvark Therapeutics Inc. | ARD-201 - (POWER) | Obesity | Phase 2 | Trial Planned | oral | Endocrinology |
| Aardvark Therapeutics Inc. | ARD-101 - (HONOR TRIAL) | Hypothalamic Obesity | Phase 2 | Trial Planned | Oral | Endocrinology |
| AbbVie Inc. | Tavapadon - (TEMPO-1) | Early Parkinson’s disease | PDUFA | Data Released | Oral | Neurology |
